Poster Presentation

The ADC NAV-001 targets a first-in-class mesothelin epitope, deploys a novel payload, and is refractory to CA125 inhibition

 

Poster Presentation

Block-Removed Immunoglobulin Technology (BRITE) to enhance rituximab effector function by counteracting CA125-mediated immunosuppression

 

Publication

Tumor-shed antigen CA125 blocks complement-mediated killing via suppression of C1q-antibody binding

 

Publication

Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-γ receptor engagement

 

Poster Presentation

Development of NAV-005, a humoral immuno-suppressor antagonist for the treatment of CA125-expressing cancers.

 

Publication

Block-Removed Immunoglobulin Technology to enhance rituximab effector function by counteracting CA125-mediated immunosuppression